Heatwurx (NASDAQ:PCSA) Issues Earnings Results

Heatwurx (NASDAQ:PCSA) released its quarterly earnings data on Friday. The company reported ($1.19) EPS for the quarter, Zacks reports.

Heatwurx Stock Performance

NASDAQ PCSA traded down $0.07 on Friday, hitting $2.43. The stock had a trading volume of 49,930 shares, compared to its average volume of 647,212. The firm has a 50-day moving average of $2.23 and a 200-day moving average of $2.50. Heatwurx has a 52-week low of $1.67 and a 52-week high of $14.24. The company has a market capitalization of $6.73 million, a price-to-earnings ratio of -0.26 and a beta of 0.99.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.